What Medicare's GLP-1 expansion reveals about the future of payer access
On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge...
On July 1, 2026, the Centers for Medicare and Medicaid Services (CMS) launched the Medicare Bridge...
Understanding how the IRA’s multiple provisions interact to induce cost-related change The...
With a few years now into the enactment of the Inflation Reduction Act (IRA), the law continues...
As part of its many provisions, the Inflation Reduction Act (IRA) includes a dramatic...
FDA has made its expectations for RWE clearer and more structured through recent guidance and...
Regulatory decision-making depends on evidence that reflects how medical products perform in...
When two federal agencies, the National Center for Science and Engineering Statistics (NCSES) and...
Government health agencies are increasingly turning to real-world data (RWD) for public health...
A new peer-reviewed study from the Centers for Disease Control and Prevention (CDC) highlights the...
Privacy preserving record linkage keeps data de-identified A single healthcare journey generates...
The therapeutic market that you know is shaped by the healthcare data that you can see. But when critical medical, specialty, clinical or longitudinal signals are absent from that view, the picture (and the decisions based on it) is less clear.